We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+25.95%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$269M
AUM Growth
-$59.3M
(-18%)
Cap. Flow
-$75.4M
Cap. Flow
% of AUM
-28.03%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
84
New
37
Increased
10
Reduced
12
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$20.6M |
| 2 |
Medtronic
MDT
|
+$13.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$8.29M |
| 4 |
Legend Biotech
LEGN
|
+$7.63M |
| 5 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$7.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$17.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$17.5M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$17M |
| 4 |
ARK Innovation ETF
ARKK
|
+$14.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.08% |
| 2 | Financials | 0.24% |
| 3 | Industrials | 0.21% |
| 4 | Energy | 0.12% |
| 5 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Editas Medicine
EDIT
$396M
| $3.05M | 1.13% |
+370,877
| New | +$3.23M |
|
|
MRUS
27
DELISTED
Merus
MRUS
| $2.68M | 1% |
+101,691
| New | +$2.23M |
|
28
Natera
NTRA
$38.3B
| $2.58M | 0.96% |
+52,964
| New | +$2.7M |
|
29
Roivant Sciences
ROIV
$24.5B
| $2.04M | 0.76% |
202,406
-142,124
| -41% | -$1.27M |
|
|
VTYX
30
DELISTED
Ventyx Biosciences
VTYX
| $1.9M | 0.7% |
57,800
-95,042
| -62% | -$3.28M |
|
|
ATXS
31
DELISTED
Astria Therapeutics
ATXS
| $1.87M | 0.69% |
224,074
-50,937
| -19% | -$588K |
|
32
Vera Therapeutics
VERA
$2.3B
| $1.75M | 0.65% |
+108,928
| New | +$984K |
|
|
MRSN
33
DELISTED
Mersana Therapeutics
MRSN
| $1.41M | 0.52% |
+17,132
| New | +$2.51M |
|
|
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.31M | 0.49% |
+41,292
| New | +$1.27M |
|
35
PMV Pharmaceuticals
PMVP
$59.2M
| $992K | 0.37% |
+158,413
| New | +$830K |
|
36
Immatics
IMTX
$1.18B
| $947K | 0.35% |
+82,052
| New | +$766K |
|
37
Xenon Pharmaceuticals
XENE
$6.06B
| $933K | 0.35% |
24,221
-197,509
| -89% | -$7.85M |
|
38
Protagonist Therapeutics
PTGX
$8.79B
| $932K | 0.35% |
33,750
-99,702
| -75% | -$2.5M |
|
|
MRTX
39
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $874K | 0.33% |
+24,201
| New | +$997K |
|
40
Schrodinger
SDGR
$1.13B
| $822K | 0.31% |
+16,462
| New | +$556K |
|
41
Cogent Biosciences
COGT
$6.65B
| $792K | 0.29% |
+66,885
| New | +$767K |
|
|
CBAY
42
DELISTED
Cymabay Therapeutics
CBAY
| $773K | 0.29% |
+70,588
| New | +$657K |
|
43
Aldeyra Therapeutics
ALDX
$92.9M
| $613K | 0.23% |
+73,067
| New | +$720K |
|
|
INBX
44
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $396K | 0.15% |
+15,268
| New | +$357K |
|
|
KYNB
45
PUT
Kyntra Bio
KYNB
$27.2M
| $331K | 0.12% |
+4,900
| New | +$2.03M |
|
46
Amphenol
APH
$198B
| $223K | 0.08% |
+5,258
| New | +$204K |
|
47
Dover
DOV
$27.6B
| $223K | 0.08% |
+1,512
| New | +$216K |
|
48
Hartford Financial Services
HIG
$38.9B
| $219K | 0.08% |
+3,034
| New | +$213K |
|
49
Prudential Financial
PRU
$42.4B
| $217K | 0.08% |
+2,463
| New | +$206K |
|
50
Colgate-Palmolive
CL
$73.1B
| $208K | 0.08% |
+2,701
| New | +$209K |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Tri Locum Partners held 84 positions worth $269M, down 18% from $328M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Tri Locum Partners withdrew a net $75.4M in Q2 2023, closing 25 positions and reducing 12 holdings. Its most notable exit was Abbott, an estimated $17.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Financials and Industrials.
Against the trend, Tri Locum Partners opened a new position in Johnson & Johnson worth $21.1M.
- Tri Locum Partners's largest Q2 2023 buy was Johnson & Johnson: 127,362 shares worth $21.1M.
- Tri Locum Partners added most to Eli Lilly in Q2 2023, an estimated $4.16M increase.
- Tri Locum Partners's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $17.5M.
- Tri Locum Partners fully exited Abbott in Q2 2023, selling an estimated $17.7M.
- Tri Locum Partners's ten largest holdings make up 56% of its $269M portfolio in Q2 2023.
- Tri Locum Partners opened 37 new positions and closed 25 in Q2 2023.
- Tri Locum Partners's portfolio value fell 18% quarter-over-quarter to $269M.
Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.